How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

779 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Help Versus Hope: Acetylcholinesterase Inhibitors in Alzheimer?s Disease

levels of care that often extend beyond the capabilities of family caretakers and result in high rates of patient placement in nursing homes. Preventing and reversing the dementia seen in AD in order to increase quality of life among these patients is the goal of treatment. Nevertheless, the backbone of Alzheimer’s treatment remains acetylcholinesterase inhibitors (CIs) such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). Memantine (Namenda), which is also approved (...) about the benefits of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease? Numerous studies investigating the effects of CI treatment on AD progression have yielded results that many find disappointing. One such study followed 2853 persons with Alzheimer’s disease to assess for changes in Mini-Mental State Examination (MMSE) score after treatment with donepezil, rivastigmine, or galantamine [8]. By 9 months, only 15.7% of patients responded to treatment, with two-thirds

2014 Clinical Correlations

162. Screening for cognitive impairment in older adults: a systematic review for the US Preventive Services Task Force

meaningful. Donepezil reduced scores by -2.03 (95% CI -2.68 to -1.38), galantamine by -2.25 (95% CI -2.94 to -1.55) and rivastigmine by -3.06 (95% CI -4.48 to -1.65). The 10 fair to good quality trials of memantine showed a pooled reduction in ADAS-cog score of -1.36 (95% CI -2.02 to -0.7). Several other interventions were considered including aspirin dietary supplements: none showed any significant benefit. AChEIs increased the risk of withdrawal due to adverse events (donepezil RR 1.79, 95% CI 1.50

Full Text available with Trip Pro

2013 DARE.

164. Serotonergic and cholinergic modulation of functional brain connectivity: A comparison between young and older adults. (PubMed)

) and the acetylcholinesterase inhibitor galantamine (8 mg) was measured in 12 young and 17 older volunteers during a randomized, double blind, placebo-controlled, crossover study. A powerful dataset consisting of 522 RS-fMRI scans was obtained by acquiring multiple scans per subject before and after drug administration. Group × treatment interaction effects on voxelwise connectivity with ten functional networks were investigated (p < .05, FWE-corrected) using a non-parametric multivariate analysis technique (...) with cerebrospinal fluid, white matter, heart rate and baseline measurements as covariates. Both groups showed a decrease in sensorimotor network connectivity after citalopram administration. The comparable findings after citalopram intake are possibly due to relatively similar serotonergic systems in the young and older subjects. Galantamine altered connectivity between the occipital visual network and regions that are implicated in learning and memory in the young subjects. The lack of a cholinergic response

2018 NeuroImage

165. Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. (PubMed)

of the nicotinic antagonist mecamylamine on a battery of cognitive and neurophysiological test with coadministration of a placebo, nicotine or galantamine in order to reverse the cognitive impairment caused by mecamylamine.Thirty-three healthy subjects received a single oral dose of 30 mg of mecamylamine (or placebo) in combination with either 16 mg of oral galantamine or 21 mg of transdermal nicotine (or its double-dummy). Mecamylamine 30 mg induced significant disturbances of cognitive functions. Attention (...) and produced decrease in performance of tests evaluating motor coordination, sustained attention and short- and long-term memory. These effects could be partially reversed by the coadministration of nicotine, and to a lesser extent by galantamine.© 2018 The British Pharmacological Society.

2018 British journal of clinical pharmacology

166. An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds. (PubMed)

, we demonstrate reversal of mecamylamine-induced neurophysiological effects due to 16 mg of galantamine as well as administering 21 mg of nicotine transdermally.Our findings indicate that the mecamylamine challenge model jointly with the nAChR index-a measure of the nicotinic EEG profile-could aid future proof-of-pharmacology studies to demonstrate effects of nicotinic cholinergic compounds.This novel measure for quantifying nicotinic cholinergic effects on the EEG could serve as a useful tool

2018 Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

167. In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease (PubMed)

, and Salvadorin showed least binding energy and highest binding affinity among all the scrutinized compounds. Post-docking analyses showed the following free energy change for Albiziasaponin-A, Salvadorin, and Iso-Orientin (-9.8 to -15.0 kcal/mol) as compared to FDA approved drugs (donepezil, galantamine, and rivastigmine) for AD (-6.6 to -8.2 Kcal/mol) and interact with similar amino acid residues (Pro-266, Asp-344, Trp-563, Pro-568, Tyr-103, Tyr-155, Trp-317, and Tyr-372) with the target proteins

Full Text available with Trip Pro

2018 Frontiers in pharmacology

168. Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis Associated Cognition

(Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Tacrine (Cognex), Bethanechol (Urecholine), Memantine (Namenda) Selegiline (Eldepryl) or any other medication for cognitive impairment. Subject has a known sensitivity to the study product. Individual has a condition the chief investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of study results or put the subject at undue risk. Contacts

2018 Clinical Trials

169. Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase. Condition or disease Intervention/treatment Phase Alzheimer Disease Cholinesterase Inhibitors Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 1205 participants Allocation: Randomized (...) Experimental: Group randomized for continuing treatment Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All randomised patients will then be followed-up for two years with regular assessment of judgment criteria

2018 Clinical Trials

170. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine (PubMed)

An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug classes: cholinesterase inhibitors (ChEIs) and the NMDA-receptor antagonist memantine. Donepezil, rivastigmine and galantamine are the three ChEIs FDA-approved as first-line treatment for AD. Although they share the same

Full Text available with Trip Pro

2018 Therapeutic advances in drug safety

171. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease (PubMed)

galantamine treatment. Newer antipsychotics, including paliperidone, lurasidone, aripiprazole, ziprasidone, and BL-1020, have also been reported to exert cognitive benefits in patients with schizophrenia. Dopaminergic medications were found to improve language function in patients with Parkinson's disease. However, no beneficial effects on cognitive function were observed with dopamine agonists in patients with schizophrenia. The efficacies of nicotine and its receptor modulators in cognitive improvement

Full Text available with Trip Pro

2018 Frontiers in Psychiatry

172. New 2-Aryl-9-methyl-β-carbolinium salts as Potential Acetylcholinesterase Inhibitor agents: Synthesis, Bioactivity and Structure–Activity Relationship (PubMed)

the excellent activity with IC50 values of 0.11-0.76 μM and high selectivity toward AChE relative to butyrylcholinesterase (BChE), superior to galantamine (IC50 = 0.79 μM), a selective AChE inhibitor drug. Kinetic analysis showed that the action mechanisms of both compounds B and A are a competitive inhibition model. Structure-activity relationship analyses showed that the C = N+ moiety is a determinant for the activity. Substituents at 6, 7 or 4' site, the indole-N-alkyl and the aromatization of the C-ring

Full Text available with Trip Pro

2018 Scientific reports

173. What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink (PubMed)

their first prescription for each drug class-namely, acetylcholinesterase (AChE) inhibitors (donepezil, rivastigmine, galantamine) and N-methyl-D-aspartate (NMDA) receptor antagonists (memantine). Trend analysis using joinpoint models was then applied to identify up to two trend changes per treatment of interest.The overall trend was for increasing prescriptions in each drug class over the period in which they were studied. This was indicated by the average monthly percentage change, which was 6.0% (95

Full Text available with Trip Pro

2018 Alzheimer's research & therapy

174. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis (PubMed)

effects model.We identified 37 studies (n=1,574): 14 donepezil-based (n=568), 10 galantamine-based (n=371), 4 rivastigmine-based (n=146), and 9 memantine-based (n=489) studies. Pooled ADD+AP treatments were superior to placebo+AP in improving the overall symptoms (24 studies, 1,069 patients: standardized mean difference [SMD]=-0.34, 95% confidence interval [CI]=-0.61 to -0.08, P=0.01), negative symptoms (24 studies, 1,077 patients: SMD=-0.62, 95% CI=-0.92 to -0.32, Pcorrected=0.00018), and MMSE scores

Full Text available with Trip Pro

2018 International Journal of Neuropsychopharmacology

175. ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

caregiver or other appropriate knowledgeable informant who can reliably report on daily activities and function and signs the informed consent for participation as such. Patient must be a good surgical candidate for placement of a deep brain stimulator as judged by the DBS surgical team. Fluency (oral and written) in the language in which standardized tests will be administered. The patient is taking a stable dose of cholinesterase inhibitor (AChEI) medication (donepezil, galantamine, or rivastigmine

2018 Clinical Trials

176. DHA Brain Delivery Trial

in the last 3 months > 200 mg/day of DHA consumption using a validated questionnaire Use of donepezil, rivastigmine, galantamine and/or memantine Alcohol or drug abuse A concomitant serious disease such as active cancer treatment or HIV. Participation in a clinical trial in the last 30 days Use of anticoagulants such as Plavix or Coumadin or the newer generation blood thinners. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor

2018 Clinical Trials

177. Examining the Effects of One-Month Probiotic Treatment on Mental Fatigue

, dabigatran, ticagrelor non-steroidal anti-inflammatory drugs (NSAIDS; excluded only for daily use) over-the-counter sleep medication (not categorized as sedatives, hypnotics or anti-depressants) anti-cholinergic drugs or acetylcholinesterase inhibitors: bethanechol (Urecholine), donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl), neostigmine (Prostigmin) anti-histamines that cause drowsiness (eg. Ranitidine) pseudoephedrine and phenylephrine Currently taking (from day of screening onwards

2018 Clinical Trials

178. Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

will undergo screening assessments to determine eligibility. This study will enroll patients who are ≥50 years of age with mild to moderate Alzheimer's Disease and on a stable treatment of donepezil, rivastigmine or galantamine for ≥3 months. Patients will be randomized (using a balanced block randomization schedule) to one of two treatment groups: Group A: 10-mg Montelukast buccal film Group B: Matching placebo buccal film In addition to the global NTB composite, patients will also be evaluated using (...) Healthy Volunteers: No Criteria Inclusion Criteria: Mild to moderate Alzheimer's Disease. MMSE score of 14 - 22 CT or MRI within 18 months prior to screening indicating clinical phenotype of Alzheimer's Disease Treated daily with donepezil, rivastigmine or galantamine for ≥ 3 months All other medications for chronic conditions should have been at a stable dose for at least 2 weeks prior to first dose. No clinically meaningful abnormalities on electrocardiogram (ECG), physical examination and clinical

2018 Clinical Trials

179. Quality of the Management of Diabetes in Elderly People With Dementia in France

by the National Library of Medicine related topics: related topics: resources: Groups and Cohorts Go to Group/Cohort Intervention/treatment Case : ADRS group Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: "F00-F03", "G30", or "G31"), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine

2018 Clinical Trials

180. An Open Pilot Trial of BHV-4157

is prohibited 30 days prior to screening and during the study; Use of aminopyridine is prohibited 30 days prior to screening and during the study; Use of tricyclic antidepressants and mono-amine-oxidase (MAO) inhibitors are prohibited 30 days prior to screening and during the study; Use of any approved treatments for Alzheimer's Disease (AD). Subjects should be free of such medications (donepezil, galantamine, rivastigmine and memantine) for at least 3 months prior to Baseline with no plans to start

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>